Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

August 30, 2017

Study Completion Date

May 30, 2019

Conditions
Metastatic Breast Cancer
Interventions
DIAGNOSTIC_TEST

18F-fluorothymidine

Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes at least 10 days prior to systemic chemotherapy, and at least 10 days after first and second cycles of systemic chemotherapy.

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT04411966 - Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter